Literature DB >> 35037229

Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells.

Seitaro Terakura1, Takashi Shiina2, Makoto Murata3, Yoshitaka Adachi4, Toshiyasu Sakai4, Shingo Suzuki5, Hiroshi Hamana6, Hiroyuki Kishi6, Takehiko Sasazuki7, Hisashi Arase8,9,10, Ryo Hanajiri4, Tatsunori Goto11, Tetsuya Nishida4, Hitoshi Kiyoi4.   

Abstract

Genomic deletion of donor-patient-mismatched HLA alleles in leukemic cells is a major cause of relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Mismatched HLA is frequently lost as an individual allele or a whole region in HLA-class I, however, it is downregulated in HLA-class II. We hypothesized that there might be a difference in T cell recognition capacity against epitopes associated with HLA-class I and HLA-class II and consequently such allogeneic immune pressure induced HLA alterations in leukemic cells. To investigate this, we conducted in vitro experiments with T cell receptor-transduced T (TCR-T) cells. The cytotoxic activity of NY-ESO-1-specific TCR-T cells exhibited similarly against K562 cells with low HLA-A*02:01 expression. However, we demonstrated that the cytokine production against low HLA-DPB1*05:01 expression line decreased gradually from the HLA expression level approximately 2-log lower than normal expressors. Using sort-purified leukemia cells before and after HSCT, we applied the next-generation sequencing, and revealed that there were several marked downregulations of HLA-class II alleles which demonstrated consistently low expression from pre-transplantation. The marked downregulation of HLA-class II may lead to decreased antigen recognition ability of antigen-specific T cells and may be one of immune evasion mechanism associated with HLA-class II downregulation.
© 2021. Japanese Society of Hematology.

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation; CTL recognition; Graft-versus-host disease (GVHD); Graft-versus-leukemia effect (GVL); HLA class II downregulation; HLA mismatch

Mesh:

Substances:

Year:  2022        PMID: 35037229     DOI: 10.1007/s12185-021-03273-w

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  32 in total

1.  Escape of leukemia blasts from HLA-specific CTL pressure in a recipient of HLA one locus-mismatched bone marrow transplantation.

Authors:  Tomonori Kato; Seitaro Terakura; Makoto Murata; Kyoko Sugimoto; Miho Murase; Chisako Iriyama; Akihiro Tomita; Akihiro Abe; Momoko Suzuki; Tetsuya Nishida; Tomoki Naoe
Journal:  Cell Immunol       Date:  2012-04-11       Impact factor: 4.868

2.  HLA-haplotype loss after TCRαβ/CD19-depleted haploidentical HSCT.

Authors:  David C Shyr; Bing M Zhang; Marcelo Fernandez-Vina; Alice Bertaina; Gopin Saini; Nahid D Madani; Liora M Schultz; Shabnum Patel; Karen Kristovich
Journal:  Bone Marrow Transplant       Date:  2020-10-17       Impact factor: 5.483

3.  Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation.

Authors:  L Crucitti; R Crocchiolo; C Toffalori; B Mazzi; R Greco; A Signori; F Sizzano; L Chiesa; E Zino; M T Lupo Stanghellini; A Assanelli; M G Carrabba; S Marktel; M Marcatti; C Bordignon; C Corti; M Bernardi; J Peccatori; C Bonini; K Fleischhauer; F Ciceri; L Vago
Journal:  Leukemia       Date:  2014-11-05       Impact factor: 11.528

Review 4.  Relapse after allogeneic stem cell transplantation.

Authors:  A John Barrett; Minoo Battiwalla
Journal:  Expert Rev Hematol       Date:  2010-08       Impact factor: 2.929

5.  Reduced mortality after allogeneic hematopoietic-cell transplantation.

Authors:  Ted A Gooley; Jason W Chien; Steven A Pergam; Sangeeta Hingorani; Mohamed L Sorror; Michael Boeckh; Paul J Martin; Brenda M Sandmaier; Kieren A Marr; Frederick R Appelbaum; Rainer Storb; George B McDonald
Journal:  N Engl J Med       Date:  2010-11-25       Impact factor: 91.245

Review 6.  Hematopoietic stem cell transplantation for acute myeloid leukemia.

Authors:  Akiyoshi Takami
Journal:  Int J Hematol       Date:  2018-01-27       Impact factor: 2.490

7.  Loss of mismatched HLA in leukemia after stem-cell transplantation.

Authors:  Luca Vago; Serena Kimi Perna; Monica Zanussi; Benedetta Mazzi; Cristina Barlassina; Maria Teresa Lupo Stanghellini; Nicola Flavio Perrelli; Cristian Cosentino; Federica Torri; Andrea Angius; Barbara Forno; Monica Casucci; Massimo Bernardi; Jacopo Peccatori; Consuelo Corti; Attilio Bondanza; Maurizio Ferrari; Silvano Rossini; Maria Grazia Roncarolo; Claudio Bordignon; Chiara Bonini; Fabio Ciceri; Katharina Fleischhauer
Journal:  N Engl J Med       Date:  2009-07-30       Impact factor: 91.245

8.  Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.

Authors:  Matthew J Christopher; Allegra A Petti; Michael P Rettig; Christopher A Miller; Ezhilarasi Chendamarai; Eric J Duncavage; Jeffery M Klco; Nicole M Helton; Michelle O'Laughlin; Catrina C Fronick; Robert S Fulton; Richard K Wilson; Lukas D Wartman; John S Welch; Sharon E Heath; Jack D Baty; Jacqueline E Payton; Timothy A Graubert; Daniel C Link; Matthew J Walter; Peter Westervelt; Timothy J Ley; John F DiPersio
Journal:  N Engl J Med       Date:  2018-10-31       Impact factor: 91.245

9.  Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation.

Authors:  Max Jan; Matthew J Leventhal; Elizabeth A Morgan; Jordan C Wengrod; Anwesha Nag; Samantha D Drinan; Bruce M Wollison; Matthew D Ducar; Aaron R Thorner; Scott Leppanen; Jane Baronas; Jonathan Stevens; William J Lane; Natasha Kekre; Vincent T Ho; John Koreth; Corey S Cutler; Sarah Nikiforow; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz; R Coleman Lindsley; Benjamin L Ebert
Journal:  Blood Adv       Date:  2019-07-23

Review 10.  Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation.

Authors:  Pier Edoardo Rovatti; Valentina Gambacorta; Francesca Lorentino; Fabio Ciceri; Luca Vago
Journal:  Front Immunol       Date:  2020-02-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.